Multi-organ Responses to CHronic Physical Activity and INactivity
Conditions: Sedentary Behavior; Metabolic Syndrome; Age-related Cognitive Decline; Age-Related Sarcopenia Interventions: Behavioral: Decreased Physical Activity; Behavioral: Increased Physical activity Sponsors: University of Nottingham; Biotechnology and Biological Sciences Research Council Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
Conditions: Herpes Zoster Interventions: Biological: HZ Vaccine (IN001); Biological: Placebo; Biological: Shingrix Sponsors: Shenzhen Shenxin Biotechnology Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)
Conditions: HPV16+ Squamous Cell Carcinoma Interventions: Drug: HB-200; Other: Placebo Sponsors: Memorial Sloan Kettering Cancer Center; Hookipa Biotech GmbH; Naveris Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization
Conditions: Japanese Encephalitis Sponsors: Liaoning Chengda Biotechnology CO., LTD Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
BiVictriX Announces FDA Orphan Drug Designation and Completion of FDA INTERACT Meeting for BVX001 in the Treatment of Acute Myeloid Leukemia
Alderley Park, 17 April 2024– BiVictriX Therapeutics plc (AIM: BVX), a biotechnology company developing novel, next-generation bispecific Antibody Drug Conjugates (bxADCs) which are designed to offer substantially improved cancer cell... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 17, 2024 Category: Pharmaceuticals Source Type: clinical trials
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
Conditions: Triple-negative Breast Cancer Interventions: Drug: ATRA; Drug: Toripalimab Sponsors: First Affiliated Hospital of Zhejiang University; Shanghai Longfine Biotechnology Co., Ltd.; TopAlliance Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia
Conditions: AML, Adult Interventions: Biological: iPSC-NK cells Sponsors: Zhejiang University; Hangzhou Qihangene Biotech Co.,Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer Interventions: Drug: Alisertib; Drug: Endocrine therapy Sponsors: Puma Biotechnology, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
An Evaluation of LY007 Cell Injection for r/r B-NHL
Conditions: B-NHL Interventions: Drug: LY007 Sponsors: Ruijin Hospital; The First Affiliated Hospital with Nanjing Medical University; Shanghai Longyao Biotechnology Inc., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in China
Conditions: Pharmacokinetics Interventions: Drug: [14C] RAY1216 Sponsors: Guangdong Raynovent Biotech Co., Ltd Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults
Conditions: Healthy Interventions: Drug: ND-003 40mg; Drug: ND-003 placebo 40mg; Drug: ND-003 80mg; Drug: ND-003 placebo 80mg; Drug: ND-003 160mg; Drug: ND-003 placebo 160mg; Drug: ND-003 240mg; Drug: ND-003 placebo 240mg; Drug: ND-003 300mg; Drug: ND-003 placebo 300mg; Drug: MAD_ND003_Dose 1; Drug: MAD_placebo_Dose 1; Drug: MAD_ND003_Dose 2; Drug: MAD_placebo_Dose 2; Drug: MAD_ND003_Dose 3; Drug: MAD_ placebo_Dose 3; Drug: Food effect_Cohort 1; Drug: Food effect_Cohort 2 Sponsors: Shenzhen NewDEL Biotech, Co., Ltd; Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Study of Pharmacokinetics and Metabolism on [(14)C]ADC189
Conditions: Pharmacokinetics; Metabolism Interventions: Drug: [(14)C]ADC189 Sponsors: Jiaxing AnDiCon Biotech Co.,Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease
Conditions: Dry Eye Interventions: Drug: VVN001 Ophthalmic Solution, 5%; Drug: VVN001 Ophthalmic Solution, Vehicle Sponsors: VivaVision Biotech, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Effect of Consumption of Pep19 on Quality of Life
Conditions: Quality of Life; Obesity; Sleep Quality Interventions: Dietary Supplement: Placebo; Dietary Supplement: Pep19 2 mg; Dietary Supplement: Pep19 5 mg Sponsors: Proteimax Biotechnology Israel LTD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation
Conditions: Clostridium Tetanus Interventions: Drug: Human anti-tetanus toxin monoclonal antibody A82 / B86 injection combination preparation; Drug: Tetanus human immunoglobulin (HTIG); Drug: Whole-human anti-tetanus toxin monoclonal antibody A82 / B86 injection placebo; Biological: Adsorbed tetanus vaccine (TT) Sponsors: Changchun BCHT Biotechnology Co.; The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine; Anning City First People ' s Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
